1226549-62-7

Basic information

• Product Name: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol
• Synonyms: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol
• CAS NO: 1226549-62-7
• Molecular Weight: 452.469
• Mol File: 1226549-62-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol(1226549-62-7)
• EPA Substance Registry System: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol(1226549-62-7)

Safety Data

• Hazardous Substances Data: 1226549-62-7(Hazardous Substances Data)

Upstream product

• 1226548-51-1 (2S)-2-[(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)amino]-2-phenylethanol 
• 13331-27-6 m-nitrobenzene boronic acid 
• 1073135-81-5 5-bromo-4-chloro-6-phenylfuro[2,3-d]pyrimidine 
• 65148-07-4 4-chloro-5,6-diphenylfuro[2,3-d]pyrimidine 

Downstream Products

• 1226549-64-9 (2S)-2-{[5-(3-aminophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol 

Relevant articles and documents

Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer

Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine 2, which contains a (S)-2-phenylglycinol

Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors

Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.